Product Information
XARELTO 1 MG/ML SUSPENSION is a brand product labeled by Janssen Pharmaceuticals Inc., priced at $3.7743 per ML under NDC 50458057501. Its NADAC has been published 85 times since Feb 19, 2025.
FDA first approved this application on Dec 20, 2021. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
The High Outlier badge above means this manufacturer's average price in the rivaroxaban market falls above Q3 + 1.5·IQR across all competing manufacturers. We only apply this flag in markets with four or more competitors. Full definition: glossary → outlier.
Strength
155 mg/1
Manufacturer
Janssen Pharmaceuticals Inc.NDC
50458057501
Classification
Brand
Dosage Form
GRANULE, FOR SUSPENSION
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
RIVAROXABANApproval Type
New Drug (NDA)
FDA Application
NDA215859FDA Approved
12/20/2021
TE Code
AB
On Market Since
12/1/2021
Pharmacological Classes
Price Statistics
The NADAC for XARELTO 1 MG/ML SUSPENSION has been published 85 times since Feb 19, 2025, and over the history we have for it it has held within roughly two percent of its current level. The table below summarizes its recorded NADAC range and movement.
| Current price | $3.7743 per ML |
|---|---|
| All-time high | $3.7811 (Jul 15, 2026) |
| All-time low | $3.6787 (Dec 17, 2025) |
| 52-week high | $3.7811 |
| 52-week low | $3.6787 |
| Median price | $3.7232 |
| Average price | $3.7256 |
| Largest weekly change | +2.3% (Feb 11, 2026) |
| Weeks tracked | 85 |
| Tracking since | Feb 19, 2025 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the rivaroxaban market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Janssen Pharmaceuticals Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
rivaroxaban market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Factor Xa Inhibitor class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of XARELTO 1 MG/ML SUSPENSION?
The current National Average Drug Acquisition Cost (NADAC) for XARELTO 1 MG/ML SUSPENSION, manufactured by Janssen Pharmaceuticals Inc., is $3.7743 per ML (NDC 50458057501), effective Sep 30, 2026.
How has the price of XARELTO 1 MG/ML SUSPENSION changed over time?
Over the history we have for it, the NADAC for XARELTO 1 MG/ML SUSPENSION has held within roughly two percent of its current level. It has been tracked across 85 weekly CMS publications since Feb 19, 2025.
What are the highest and lowest recorded NADAC prices for XARELTO 1 MG/ML SUSPENSION?
Since Feb 19, 2025, the NADAC for XARELTO 1 MG/ML SUSPENSION has ranged from a low of $3.6787 (Dec 17, 2025) to a high of $3.7811 (Jul 15, 2026), with a median of $3.7232 per ML.
Are there cheaper alternatives to XARELTO 1 MG/ML SUSPENSION?
No other NADAC-published product currently shares the active ingredient and strength of XARELTO 1 MG/ML SUSPENSION in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures XARELTO 1 MG/ML SUSPENSION?
XARELTO 1 MG/ML SUSPENSION (NDC 50458057501) is labeled by Janssen Pharmaceuticals Inc., and CMS classifies it as a brand product.